Secarna Addresses Undruggable Targets With Antisense Platform

At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications. 

scientists gathered around a computer analyzing research
scientists gathered analyzing research • Source: Shutterstock

Founded in 2015, Secarna Pharmaceuticals entered the antisense drug discovery and development space with the goal of addressing high unmet medical needs using a never-before-seen artificial intelligence (AI)-powered platform. It is designed to select and synthesize antisense oligonucleotides (ASOs) against challenging or historically undruggable targets across indications. 

Alexander Gebauer, the company’s CEO and managing director, firmly believes that with the help of this platform, ASO therapies can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo